Insider buying last 90 days
No open-market insider purchases were filed for TRVI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TRVI insider filing, plotted on the chart in Gekko.Open TRVI in Gekko
NASDAQ: TRVI
Trevi Therapeutics (TRVI) Stock Analysis & Forecast
Oct 12 close
$12.93−0.26 (−2.0%)
Gekko Brief
Oct 12 closeTrevi Therapeutics closed at $12.93 on 12 October 2026, -2% on the day. The price sits between the 50-day ($16.26) and 200-day ($14.28) moving averages, inside a 52-week range of $9.28 to $20.22. The GekkoIndex reads 75.6, in the Buying zone, up 1.3 points over five sessions. Gekko Fair Value is $19.09, so the price is 32.3% below it.
The next earnings report is due on 12 November 2026, 31 days away (after close). Over the last 8 reports the company beat the earnings estimate 3 times, with an average move of 4.6% across the report. Seasonally, the next 20 trading days from this point averaged -4% over the last 5 years, rising in 3 of them.
10 firms rate the stock: 10 buy, 0 hold and 0 sell, with a consensus target of $28.18. A typical daily move is about 5.3%, and a typical 20-day move about 12.5%. On the swing-trade checklist, 3 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Oct 12, 2026 close.
Trevi Therapeutics price vs fair value
Close $12.93200-day averageGekko Fair Value $19.09
Trevi Therapeutics quick facts
- Market cap
- $1.84B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.34
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.98
- Volume
- 4.72M avg 2.78M
- 1-year return
- +30.3%
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±12.5%
- 50-day average
- $16.26
- 200-day average
- $14.28
- Next earnings
- Nov 12 after close
- Shares outstanding
- 142.5M
Trevi Therapeutics swing-trade checklist
Trevi Therapeutics scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $12.93 sits between the 50-day ($16.26) and 200-day ($14.28) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
75.6, Buying
Reading 75.6 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
32.3% below
Price is 32.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−4.0% on average
From this point in the calendar, the next 20 trading days averaged −4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Trevi Therapeutics stock chart and price history
Trevi Therapeutics closed at $12.93 on Oct 12, 2026, +30.3% over the past year, inside a 52-week range of $9.28 to $20.22.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −18.7%
- 3 months
- −27.8%
- 6 months
- −3.0%
- 1 year
- +30.3%
The full TRVI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TRVI in Gekko
Follow Trevi Therapeutics through every session
Put TRVI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TRVI in GekkoFree for 7 days. No credit card required.
About Trevi Therapeutics
Trevi Therapeutics develops Haduvio, a treatment candidate aimed at hard-to-manage conditions rooted in the nervous system. The product is an extended-release oral version of nalbuphine, and it is being tested in Phase IIb/III trials for two uses: chronic pruritus, a severe form of itching, and the persistent cough that affects patients with idiopathic pulmonary fibrosis. As a clinical-stage company, Trevi has not yet brought a product to market.
The company's ability to pursue this work rests on a licensing arrangement with Endo Pharmaceuticals Inc., which gives Trevi the rights to develop and sell various formulations containing nalbuphine hydrochloride. This agreement underpins its research and any future commercialization efforts tied to the compound.
Trevi Therapeutics was founded in 2011 and operates out of New Haven, Connecticut. Its shares trade on the NASDAQ under the ticker TRVI.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- trevitherapeutics.com
Trevi Therapeutics GekkoIndex: the smart money zone
Trevi Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 75.6, in the Buying zone, up 1.3 points over five sessions.
75.6Buying
Up 1.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 17 | Not available | |||
| Accumulation | 159 | +4.1% | +16.1% | ||
| Neutral | 436 | +1.7% | +6.0% | ||
| Distribution | 58 | −0.1% | +2.7% | ||
| Selling | 12 | +13.3% | +40.9% | ||
Average TRVI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the TRVI price, zone by zone.Track TRVI in Gekko
Is Trevi Therapeutics stock overvalued? Gekko Fair Value
Trevi Therapeutics trades 32.3% below Gekko Fair Value of $19.09, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Trevi Therapeutics shares are worth, recalculated every trading day.
$19.09
Gekko Fair Value, Oct 10, 2026
32.3% Undervalued
At the end of Aug 2026 the price was 32.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TRVI in Gekko
Trevi Therapeutics insider and Congress trading
No open-market insider purchases were filed for Trevi Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TRVI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TRVI, plotted on the chart in Gekko.Open TRVI in Gekko
Buybacks
Trevi Therapeutics has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $1.53M
- As a share of market cap
- 0.08%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds TRVI.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Trevi Therapeutics earnings: next date and track record
Trevi Therapeutics reports on Nov 12, 2026, after the close (31 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 12, 2026
Expected after the close, 31 days away
- EPS estimate
- −$0.13
3 of 8reports beat the EPS estimate
±4.6%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, May 5, 2026 AI summary
- What they said
- Trevi Therapeutics presented a confident, execution-focused update highlighting regulatory alignment, clinical development progress, and an improved financial position. Management reported a positive FDA meeting for the IPF-related chronic cough program, finalized Phase III protocols, and plans to initiate two pivotal IPF trials (one this quarter and a second in H2 2026). They also plan an adaptive Phase II/III design for a non-IPF-ILD chronic cough program and anticipate initiating that trial in H2 2026 following a meeting request/protocol discussion with the FDA. The company recently completed an underwritten common stock offering (net proceeds of $162M in April 2026) and ended Q1 2026 with approximately $172M in cash/securities (not including the offering), extending runway into 2030 and funding development through key value inflection points including potential FDA approval for the IPF program. Management emphasized readiness to run multiple programs (IPF, non-IPF-ILD, RCC), added headcount, and identified upcoming data/events (SSRE for RCC expected by Q4 2026, ATS presentations later in the month, Phase IIb/III timelines in 2027). The tone was largely constructive and confident, with factual discussion of trial design features (sample size re-estimation, placebo run-in in RCC), IP strategy (label-enablement patents), and commercial considerations (dyspnea as a value driver, payer discussions).
- Guidance
- - Initiate first of two Phase III IPF-related chronic cough studies this quarter (Q2 2026), second Phase III study in H2 2026. - Plan to submit meeting request/protocol to FDA for adaptive Phase II/III non-IPF-ILD chronic cough program; expect to initiate that trial in H2 2026 if agreed with FDA. - Sample size re-estimation (SSRE) readout for RCC trial expected by Q4 2026 (halfway point of trial). - Cash runway extended into 2030; cash + marketable securities of ~$172M at end of Q1 2026 (does not include $162M net proceeds from April 2026 offering).
- Risks flagged
- - Clinical trial execution risks: potential for futility or need to upsize trials following SSRE; placebo response variability (especially in RCC). - Competitive risk: P2X3 and inhaled therapeutics in development could alter competitive positioning and enrollment dynamics. - Regulatory risk: FDA alignment is ongoing for non-IPF-ILD; approvals and labeling remain uncertain. - Financial/commercial risk: current runway excludes commercial launch costs; success depends on future financing, execution, and payer uptake. - General market and development risks as noted in company filings (Form 10-K and subsequent updates).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 5, 2026 | −$0.09 est −$0.07 | — | −0.8% |
| Mar 17, 2026 | −$0.06 est −$0.10 | — | −4.2% |
| Nov 13, 2025 | −$0.08 est −$0.10 | — | −4.1% |
| Aug 7, 2025 | −$0.09 est −$0.10 | — | +2.1% |
| May 8, 2025 | −$0.09 est −$0.09 | — | −0.9% |
| Nov 6, 2024 | −$0.13 est −$0.12 | — | −4.0% |
| Aug 8, 2024 | −$0.12 est −$0.11 | — | +10.4% |
| May 7, 2024 | −$0.11 est −$0.09 | — | −10.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Trevi Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Trevi Therapeutics is $28.18, +117.9% from the last close, from 10 firms rating the stock in the last 90 days.
$28.18consensus 12-month target, +117.9% from the last close
Now $12.93Avg $28.18
Low $23High $40
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | H.C. Wainwright | $24 | +85.6% |
| Aug 13 | JonesTrading | $28 | +116.6% |
| Aug 11 | H.C. Wainwright | $24 | +85.6% |
| Aug 10 | Morgan Stanley | $23 | +77.9% |
| Aug 7 | Cantor Fitzgerald | $30 | +132.0% |
−4.0%average move over the next 20 trading days in the last 5 years
±5.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Trevi Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Trevi Therapeutics averaged −4.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.9% | 3 of 5 |
| Next 10 trading days | −0.3% | 3 of 5 |
| Next 15 trading days | +0.4% | 3 of 5 |
| Next 20 trading days | −4.0% | 3 of 5 |
| Next 30 trading days | −10.5% | 2 of 5 |
For scale, TRVI’s typical 20-trading-day move in either direction is about 12.5%.
Trevi Therapeutics market cap and key statistics
Trevi Therapeutics’s market cap is $1.84B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.84B
- EPS, TTM
- −$0.34
- Gekko Fair Value
- $19.09
Trading
- Volume
- 4.72M
- Avg volume, 20 days
- 2.78M
- 52-week high
- $20.22
- 52-week low
- $9.28
- Shares outstanding
- 142.5M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -19.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.98
- Typical daily move
- ±5.3%
- Typical 20-day move
- ±12.5%
Trevi Therapeutics stock news this week
Coverage of Trevi Therapeutics this week reads positive: 2 positive, 1 neutral and 0 negative headlines.
- Trevi Therapeutics Q2 2026 Earnings Call TranscriptBenzinga, Oct 12
- Trevi Therapeutics Inc Share Price - TRVI, RNS News, Articles, Quotes, & Charts (NASDAQ: TRVI)Proactive financial news, Oct 8
- BMO reiterates Trevi Therapeutics stock rating after rival study fails By Investing.comInvesting.com Canada, Oct 7
Trevi Therapeutics peers
Trevi Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Trevi Therapeutics stock FAQ
What is Trevi Therapeutics’s market cap?
Trevi Therapeutics’s market cap is $1.84B at the Oct 12, 2026 close of $12.93, with 142.5M shares outstanding.
What is the Trevi Therapeutics stock forecast?
The consensus analyst 12-month price target for Trevi Therapeutics is $28.18, +117.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Trevi Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Trevi Therapeutics is undervalued: the Oct 12, 2026 close of $12.93 is 32.3% below Gekko Fair Value of $19.09. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Trevi Therapeutics report earnings next?
Trevi Therapeutics is expected to report on Nov 12, 2026, after the market closes (31 days away). Analysts expect earnings of −$0.13 per share. Trevi Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 4.6% on average across the report.
What is Trevi Therapeutics’s 52-week high and low?
Trevi Therapeutics’s 52-week high is $20.22 and its 52-week low is $9.28; it closed at $12.93 on Oct 12, 2026, +30.3% over the past year.
Is Trevi Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Trevi Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.